ICaPath
ICaPath is pioneering novel drug delivery technologies, focusing on combining PLGA nanoparticles with cytokines for advanced immunotherapy. Their patented technology enables the controlled, sustained release of cytokines in low doses, mitigating toxicity and enhancing immune efficacy for treating advanced cancers. Their lead therapeutic, ICP-001, is an Interleukin-12 encapsulated in PLGA nanoparticles, designed for systemic immunostimulation. The company utilizes a proprietary immuno-surveillance system for precision medicine and data generation, with plans to integrate AI for improved treatment strategies. ICaPath has a global patent for its PLGA nanoparticle technology and is preparing for first-in-human clinical trials.
ICaPath
ICaPath is pioneering novel drug delivery technologies, focusing on combining PLGA nanoparticles with cytokines for advanced immunotherapy. Their patented technology enables the controlled, sustained release of cytokines in low doses, mitigating toxicity and enhancing immune efficacy for treating advanced cancers. Their lead therapeutic, ICP-001, is an Interleukin-12 encapsulated in PLGA nanoparticles, designed for systemic immunostimulation. The company utilizes a proprietary immuno-surveillance system for precision medicine and data generation, with plans to integrate AI for improved treatment strategies. ICaPath has a global patent for its PLGA nanoparticle technology and is preparing for first-in-human clinical trials.